Table 4

Autoantibodies to WIBG, GABARAPL2, ZNF706 peptides in patients with early RA

WIBG P22, ZNF706 P1 and GABARAPL2 P15 combination

Anti-CCP

RF

WIBG P22

ZNF706 P1

GABARAPL2 P15


RA <1 year (n = 60) vs 106 controls (AS, PsA, SLE, and healthy)

Sensitivity (%)

72

70

30

35

37

45

Specificity (%)

100

nd

95

100

95

92

PPV (%)

100

nd

78

100

81

75

NPV (%)

86

nd

71

73

73

75

RA <1 year negative for anti-CCP (n = 17) vs 106 controls (AS, PsA, SLE, and healthy)

Sensitivity (%)

0

29

12

6

23

41

Specificity (%)

nd

nd

95

100

95

92

PPV (%)

nd

nd

18

10

31

44

NPV (%)

nd

nd

87

86

88

91

RA <1 year negative for RF (n = 17) vs 106 controls (AS, PsA, SLE, and healthy)

Sensitivity (%)

29

0

12

12

18

35

Specificity (%)

100

nd

95

100

95

92

PPV (%)

100

nd

29

100

37

40

NPV (%)

90

nd

87

88

88

90

RA <1 year negative for anti-CCP and RF (n = 12) vs 106 controls (AS, PsA, SLE, and healthy)

Sensitivity (%)

0

0

8

8

25

42

Specificity (%)

nd

nd

95

100

95

92

PPV (%)

nd

nd

17

100

37

36

NPV (%)

nd

nd

90

91

92

93


WIBG, within BGCN homolog (Drosophila); GABARAPL2, GABA(A) receptor-associated protein-like 2; ZNF706, zinc finger protein 706; RA, rheumatoid arthritis; CCP, cyclic citrullinated peptide; RF, rheumatoid factor; AS, ankylosing spondylitis; PsA, psoriatic arthritis; SLE, systemic lupus eryth ematosus; SSc, systemic sclerosis; PPV, positive predictive value; NPV, negative predictive value; nd, not determined.

Charpin et al. Arthritis Research & Therapy 2013 15:R78   doi:10.1186/ar4255

Open Data